Antitrust matters are rarely isolated within a single state or federal agency or jurisdiction. We represent clients facing multi-dimensional antitrust challenges on the transactional, regulatory and litigation fronts, mobilizing an unmatched combination of courtroom excellence, government experience and legal, economic and academic prowess on our clients’ behalf.
Cigna announced that the Antitrust Division of the U.S. Department of Justice cleared Cigna’s $67 billion acquisition of pharmacy benefits manager Express Scripts Holding Company, terminating the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.
In a victory for client Nomura and other defendant banks, Paul, Weiss and other joint defense firms won the dismissal of a consolidated class action alleging that Nomura and other major global financial institutions conspired to manipulate prices in the multitrillion-dollar global market for supranational, sub-sovereign and agency (SSA) bonds.
Paul, Weiss secured a significant antitrust appellate victory for global medical technology company Becton Dickinson & Company (BD).
As reported in The Wall Street Journal, Bloomberg, Reuters and other media outlets, Paul, Weiss client Elanco U.S., Inc., a subsidiary of Paul, Weiss client Eli Lilly and Company, announced an agreement to acquire Boehringer Ingelheim Vetmedica, Inc.'s U.S. feline, canine and rabies vaccines portfolio, as well as a fully integrated manufacturing and R&D site, for $885 million.
A federal district court in Washington, D.C. rejected an application to preliminarily enjoin Paul, Weiss client Mastercard Incorporated from enforcing its ATM rules.
Paul, Weiss has been named Benchmark Litigation's "Antitrust Firm of the Year" for 2015. Litigation partners Aidan Synnott, Jacqueline Rubin and William Michael received the award for the firm on January 29 at the Essex House in New York at the second annual nationwide U.S. Benchmark Litigation Awards ceremony.